Showing results (11-20 of 432) with videos related to
Sort By:
Pageof 44
Expert Opinion on Drug Metabolism & Toxicology|September 13, 2019
Drug-drug interactions when treating HIV-related metabolic disordersMaria Del Mar Gutierrez, Mª Gracia Mateo, Noemí Corbacho, et al.Expert Opinion on Pharmacotherapy|February 26, 2021
Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)María Del Mar Gutierrez, Isabel Mur, María Gracia Mateo, et al.Enfermedades Infecciosas Y Microbiologia Clinica|December 17, 2008
[Toxicogenetics of antiretroviral treatment (1): lipodystrophy, metabolic perturbations and atherosclerosis]M Mar Gutiérrez Maciá, M Gracia Mateo García, Francesc Vidal Marsal, et al.Expert Opinion on Drug Metabolism & Toxicology|October 18, 2011
Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapyFrancesc Vidal, Pere Domingo, Consuelo Viladés, et al.Enfermedades Infecciosas Y Microbiologia Clinica|February 2, 2010
[Role of etravirine in combination antiretroviral therapy]Pere DomingoExpert Opinion on Drug Metabolism & Toxicology|November 22, 2013
Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patientsJoaquim Peraire, Consuelo Viladés, Yolanda M Pacheco, et al.AIDS Reviews|March 11, 2010
Pharmacogenetics of adverse effects due to antiretroviral drugsFrancesc Vidal, Félix Gutiérrez, Mar Gutiérrez, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2005
Lack of association of SDF-1 3'A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 yearsFrancesc Vidal, Joaquim Peraire, Pere Domingo, et al.Radiologic Clinics of North America|May 9, 2022
Pulmonary Infections in People Living with HIVTomás Franquet, Pere DomingoEnfermedades Infecciosas Y Microbiologia Clinica|February 18, 2011
[Management of antiretroviral drug toxicity]Pere Domingo, Fernando LozanoPageof 44